

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 12b-25

NOTIFICATION OF LATE FILING

SEC FILE NUMBER  
001-37392

CUSIP NUMBER  
03763A207

(Check one):

Form 10-K  
 Form N-CEN

Form 20-F  
 Form N-CSR

Form 11-K

Form 10-Q

Form 10-D

For Period Ended: December 31, 2025

Transition Report on Form 10-K  
 Transition Report on Form 20-F  
 Transition Report on Form 11-K  
 Transition Report on Form 10-Q

For the Transition Period Ended: \_\_\_\_\_

*Read Instructions (on back page) Before Preparing Form. Please Print or Type.*

**Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.**

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates: \_\_\_\_\_

**PART I – REGISTRANT INFORMATION**

**Astrana Health, Inc.**

Full Name of Registrant

**Not applicable**

Former Name if Applicable

**1668 S. Garfield Avenue, 2nd Floor**

Address of Principal Executive Office (*Street and Number*)

**Alhambra, California 91801**

City, State and Zip Code

**PART II – RULES 12b-25(b) AND (c)**

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

- (a) The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
- (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
- (c) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

**PART III – NARRATIVE**

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

Astrana Health, Inc. (the "Company") is unable to timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2025 (the "2025 Form 10-K") within the prescribed time period without unreasonable effort or expense. The 2025 Form 10-K cannot be filed by the prescribed due date because additional time, resources and effort are required to complete work related to the Company's financial reporting and close procedures, specifically as a result of the Company's acquisition of certain entities.

In connection with the filing of the 2025 Form 10-K, when made, the Company anticipates reporting a material weakness in the Company's internal control over financial reporting, which is expected to relate to, but may not be limited to, the Company's acquisition and purchase accounting processes. As a result of the expected material weakness, the Company believes that its internal control over financial reporting was not effective, and its disclosure controls and procedures were not effective, as of December 31, 2025. The Company is developing a remediation plan that will be described further in the 2025 Form 10-K.

The Company currently expects to file the 2025 Form 10-K within the fifteen-day extension period provided under Rule 12b-25 of the Securities Exchange Act of 1934, as amended. Although the 2025 Form 10-K is not completed, the Company expects that the financial statements in the 2025 Form 10-K will be substantially consistent with the financial information reported in the earnings release for the quarter and year ended December 31, 2025.

**Forward-Looking Statements**

